Pharsight

Drugs that contain Asciminib Hydrochloride

1. Scemblix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(9 years from now)

US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 29, 2026
Orphan Drug Exclusivity (ODE) Oct 29, 2028

NCE-1 date: 2025-10-29

Market Authorisation Date: 29 October, 2021

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: TABLET;ORAL

More Information on Dosage

SCEMBLIX family patents

Family Patents